Logo for Enanta Pharmaceuticals Inc

Enanta Pharmaceuticals Investor Relations Material

Latest events

Logo for Enanta Pharmaceuticals Inc

Study Result

Enanta Pharmaceuticals
Logo for Enanta Pharmaceuticals

Q1 2025

10 Feb, 2025
Logo for Enanta Pharmaceuticals

Study Result

9 Dec, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies

Latest reports from Enanta Pharmaceuticals Inc

Access all reports
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. It focuses on developing its late-stage product candidates that target non-structural protein 3 protease (NS3/4A) of hepatitis C virus (HCV) and compounds targeting NS5A of HCV. The company's lead clinical candidate, paritaprevir, is developed in collaboration with AbbVie in a combination therapy regimen for the treatment of genotype 1 HCV; EDP-522 as an NS5A inhibitor for the treatment of chronic hepatitis B virus; and EDP-239 as an HCV NS3 protease inhibitor.